Dynavax Technologies Co. (DVAX) Insider Sells $38,114.37 in Stock
Dynavax Technologies Co. (NASDAQ:DVAX) insider David F. Novack sold 2,121 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $17.97, for a total value of $38,114.37. Following the transaction, the insider now directly owns 77,192 shares in the company, valued at approximately $1,387,140.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Dynavax Technologies Co. (DVAX) traded up $0.02 during midday trading on Wednesday, hitting $16.32. The company had a trading volume of 71,214 shares, compared to its average volume of 1,407,592. Dynavax Technologies Co. has a 52-week low of $5.00 and a 52-week high of $24.45. The stock has a market capitalization of $1,039.32, a price-to-earnings ratio of -8.86 and a beta of 1.05.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.32). Dynavax Technologies had a negative return on equity of 57.43% and a negative net margin of 29,099.08%. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.53 million. equities research analysts forecast that Dynavax Technologies Co. will post -1.82 earnings per share for the current fiscal year.
Several brokerages have issued reports on DVAX. Royal Bank of Canada reaffirmed a “buy” rating and set a $25.00 price objective on shares of Dynavax Technologies in a report on Friday, March 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $27.00 price objective (up previously from $25.00) on shares of Dynavax Technologies in a report on Thursday, March 8th. Cowen reaffirmed a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a report on Wednesday, February 21st. JPMorgan Chase & Co. lowered Dynavax Technologies from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $31.00 to $25.00 in a report on Wednesday, February 14th. Finally, BidaskClub raised Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Dynavax Technologies has an average rating of “Hold” and an average target price of $24.67.
TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/03/14/dynavax-technologies-co-dvax-insider-sells-38114-37-in-stock.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.